Enterprise Sponsor
Evolve Biologics is a new kind of biologics company. The company aims to provide technological
innovations that advance the possibilities and capabilities across the plasma industry.
The company’s next-generation protein extraction technology, PlasmaCap EBA®,
helps bring critical therapeutics to patients who need them. Evolve Biologics’ believes this
technology will help them deliver many critical plasma-derived therapeutics at higher levels of
purity, efficiency, and quality than existing conventional methods can,
Many of the proteins found within human blood plasma have tremendous therapeutic value in treating a
range of rare diseases and demand for continues to grow. However, conventional methods for the
extraction of a broad range of plasma proteins face certain limitations.
Evolve Biologics
has developed a new solution based on expanded bed chromatography that creates the opportunity to
develop a wide range of novel plasma-derived therapies. The company’s patented technology, PlasmaCap
EBA®, has the potential to deliver critical plasma-derived therapeutics at higher levels
of purity, efficiency, and reliability than currently available in the market and is cost-effective at
multiple scales. This represents the first major breakthrough advancement in this field in over 75
years. Evolve Biologics aims to continue to contribute to the future of healthcare by developing a
broad and innovative portfolio of plasma-derived therapeutics, with improved reliability of supply,
that ultimately improves the lives of patients with rare diseases.
